Spots Global Cancer Trial Database for High-dose Bevacizumab in Advanced Renal Carcinoma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Official Title: Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
Study ID: NCT00455975
Interventions
Study Description
Brief Summary: This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.
Detailed Description: Bevacizumab is considered a targeted drug. Targeted drugs act on specific receptors on a cell. Bevacizumab blocks receptors that help cancer cells develop blood supplies so that the cancer can grow. These specific receptors are found in greater numbers in kidney cancer. In that regard bevacizumab will be tested in 2 doses that are higher than non-kidney cancer treatments with bevacizumab. One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks. A total of 75 patients will be treated with this dose. If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg per kg by vein weekly.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Florida Cancer Specialists, Fort Myers, Florida, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Methodist Cancer Center, Omaha, Nebraska, United States
Cancer Care of Western North Carolina, Asheville, North Carolina, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Family Cancer Center, Collierville, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Peninsula Cancer Institute, Newport News, Virginia, United States
Contact Details
Name: John D. Hainsworth, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
